
    
      In and out patients evaluated for a sensory neuropathy meeting the inclusion and
      non-inclusion criteria will be proposed to enter the study

      At inclusion the SSN diagnostic score is calculated and a blood sample is tested for
      anti-FGFR3 antibody.

      Follow up: Patients positive for anti-FGFR3 antibodies will be followed and evaluated
      clinically and electrophysiologically at 1, 6 and 12 months. A blood sample is taken at 6 and
      12 months.

      A subgroup of patients negative for anti-FGFR3 antibodies will be randomly selected for
      evaluation at 1, 6 and 12 months.
    
  